Ursosiol

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6006 publications

Bile acids in the treatment of hepatobiliary diseases: rational use of UDCA.

Bile acids in the treatment of hepatobiliary diseases: rational use of UDCA.

Journal: Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti

Published: June 23, 2026

Utility of pretreatment GLOBE score as a non-invasive prognostic tool in primary biliary cholangitis.

Utility of pretreatment GLOBE score as a non-invasive prognostic tool in primary biliary cholangitis.

Journal: Immunological medicine

Published: June 12, 2026

Pharmaceutical and Nutraceutical Therapies for Liver Disease.

Pharmaceutical and Nutraceutical Therapies for Liver Disease.

Journal: The Veterinary clinics of North America. Equine practice

Published: June 11, 2026

A case of primary biliary cholangitis whose pathology changed during autoimmune hepatitis

A case of primary biliary cholangitis whose pathology changed during autoimmune hepatitis

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

Published: June 10, 2026

Ecology and engineering to modify the bile acid output of a defined microbial community.

Ecology and engineering to modify the bile acid output of a defined microbial community.

Journal: bioRxiv : the preprint server for biology

Published: June 05, 2026

Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon.

Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon.

Journal: Microbiology spectrum

Published: May 11, 2026

Primary biliary cholangitis: current insights and novel therapies.

Primary biliary cholangitis: current insights and novel therapies.

Journal: Expert review of clinical immunology

Published: May 10, 2026

COMPARATIVE EFFICACY OF PHENOBARBITAL, FLUMECINOL, AND URSODEOXYCHOLIC ACID IN THE MANAGEMENT OF HYPERBILIRUBINEMIA IN PATIENTS WITH GILBERT SYNDROME: A PROSPECTIVE COMPARATIVE STUDY.

COMPARATIVE EFFICACY OF PHENOBARBITAL, FLUMECINOL, AND URSODEOXYCHOLIC ACID IN THE MANAGEMENT OF HYPERBILIRUBINEMIA IN PATIENTS WITH GILBERT SYNDROME: A PROSPECTIVE COMPARATIVE STUDY.

Journal: Georgian medical news

Published: May 10, 2026

On the use of UDCA beyond cholestatic liver disease: How bile acid-driven intestinal GLP-1 signalling keeps the joints healthy.

On the use of UDCA beyond cholestatic liver disease: How bile acid-driven intestinal GLP-1 signalling keeps the joints healthy.

Journal: Journal of hepatology

Published: May 07, 2026

Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina.

Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina.

Journal: Technology and health care : official journal of the European Society for Engineering and Medicine

Published: April 25, 2026

Interferon-gamma-inducible protein-10 is associated to increased primary bile acids and fibrosis in primary sclerosing cholangitis.

Interferon-gamma-inducible protein-10 is associated to increased primary bile acids and fibrosis in primary sclerosing cholangitis.

Journal: The Journal of steroid biochemistry and molecular biology

Published: April 23, 2026

Prolonged cholestasis following severe neonatal echovirus 11 (genotype D5, new lineage 1) infection diagnosed by serum detection.

Prolonged cholestasis following severe neonatal echovirus 11 (genotype D5, new lineage 1) infection diagnosed by serum detection.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: April 22, 2026

Showing 1-12 of 6,006

Last Updated: 06/30/2026